Adverse events after the use of benznidazole in infants and children with Chagas disease
about
Chagas disease in the 21st century: a public health success or an emerging threat?Control and management of congenital Chagas disease in Europe and other non-endemic countries: current policies and practicesIn vitro and in vivo trypanocidal activity of H2bdtc-loaded solid lipid nanoparticlesCongenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant womenImproved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural BoliviaPopulation pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adultsHepatotoxicity in mice of a novel anti-parasite drug candidate hydroxymethylnitrofurazone: a comparison with BenznidazoleChagas' disease: pregnancy and congenital transmission.A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazoleThe epidemiological relevance of family study in Chagas diseaseMapping antigenic motifs in the trypomastigote small surface antigen from Trypanosoma cruzi.A national survey to determine prevalence of Trypanosoma cruzi infection among pregnant women in EcuadorFirst Documented Transmission of Trypanosoma cruzi Infection through Blood Transfusion in a Child with Sickle-Cell Disease in Belgium.Prevention of congenital Chagas through treatment of girls and women of childbearing age.Urban Chagas disease in children and women in primary care centres in Buenos Aires, Argentina.Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participationPharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.Chagas disease and breast-feedingTwo analogues of fenarimol show curative activity in an experimental model of Chagas disease.Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysisImmunomodulatory effects of antimicrobial agents. Part II: antiparasitic and antifungal agents.Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence.Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report.Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR.Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection.Towards a New Strategy for Diagnosis of Congenital Trypanosoma cruzi Infection.Immunoregulatory actions of melatonin and zinc during chronic Trypanosoma cruzi infection.Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.Towards Chagas disease elimination: Neonatal screening for congenital transmission in rural communities.Benzoic Acid Derivatives with Trypanocidal Activity: Enzymatic Analysis and Molecular Docking Studies toward Trans-Sialidase.The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy.Safety of benznidazole use in the treatment of chronic Chagas' disease.Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in BoliviaValidation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With BenznidazoleLimited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease
P2860
Q24594371-58E88085-BCF6-4FA3-A2C8-0B3CBBEB32ADQ26765133-7BC0135A-2F0A-4402-AA5C-1C914A4398BDQ27304890-B654FD85-0540-4FB0-929D-ECD20A07AB13Q28251886-DE0DC8B1-4971-4AA3-BBCF-C60A0949E5C1Q28533625-9D10D322-946F-43CE-9AAC-847AA0D2F1CBQ28539049-3F1AFB20-08D3-4C1E-B91B-D01B04E993E6Q28543851-01CF9DEC-8B92-48AD-AECF-66929AD42947Q33735827-46BB5C9D-9EEF-4263-9C63-EF21E34C7B99Q34596630-1558746D-524F-4193-B3A5-A8823F7C0465Q34607251-21991210-CB1B-4B02-9A1B-A81F32A8BF1CQ35122764-102C38CF-58D0-449B-9805-7AA650870500Q35272762-7FB61014-F628-496F-8DA5-D9542DA563F7Q35808368-0DE9EEAC-6DF2-44B6-BA60-7DC5FCB04F6EQ35849290-9C3B22FE-7624-40C8-97B5-8A589A9BC20AQ36059689-8F87F2FB-62A6-49F1-80A4-5FCA880FC4C3Q36278397-5333F44C-1AF2-47A5-91A6-D39A449B0776Q36720271-36FA6EE6-9A61-4807-9B1D-07067C54347FQ37261944-50CD2D32-7916-4B23-806E-DFFC403222CEQ37449720-1F1BBAC7-4551-44B4-A16E-83328F28D49AQ37557805-7CB22A4E-9AC2-4BC3-84BF-84CD726CBA07Q37991390-BB354CF7-CA44-4314-9557-9D98ACCC0D4BQ38017721-2B5BD8B1-D10E-43D7-8315-53B18896013FQ38782578-9F1EDD6F-92A7-4F69-8963-9296DF4A9CE6Q38867072-55C00D00-196E-4133-A687-7044A1E8C3E8Q38959933-CD990D30-C02F-4233-B55D-BBDBC3D04E24Q39372756-C861F969-5A7B-4AD5-9190-DFCAD57A2EF0Q39508383-9BDF885C-45B1-4A4D-91E4-07D56B1CE775Q40331334-3FCF4B0C-658D-420C-9EC3-3747B6784868Q41528104-B1E6B851-357F-4401-B498-057A93FFCCE5Q41890035-91666E67-8167-4D03-A899-25CD76CB6597Q42220257-51E510DB-E7B0-45C0-82F4-FB6E04B3D329Q42706614-A2DFD5BD-691F-4CDD-9EEC-093216EA9A44Q48102865-1BBE47FE-C92B-439B-AA77-16783CAD449FQ48243287-EE329AA0-99A9-41CA-AC39-F50BC2C744B5Q51040694-4DCFB834-84C8-4839-A754-AD739F6D56BAQ51360425-DB5C05FC-0CF2-4780-9120-96824D022567Q56829258-338D8F96-9E91-4CFD-B775-EBF37BC8F1B9Q58573679-8549AD33-8CC4-465C-97EF-3238531A8C90Q58862886-F567A636-3137-4927-8F45-A2FF0427BDCD
P2860
Adverse events after the use of benznidazole in infants and children with Chagas disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Adverse events after the use of benznidazole in infants and children with Chagas disease
@ast
Adverse events after the use of benznidazole in infants and children with Chagas disease
@en
Adverse events after the use of benznidazole in infants and children with Chagas disease
@nl
type
label
Adverse events after the use of benznidazole in infants and children with Chagas disease
@ast
Adverse events after the use of benznidazole in infants and children with Chagas disease
@en
Adverse events after the use of benznidazole in infants and children with Chagas disease
@nl
prefLabel
Adverse events after the use of benznidazole in infants and children with Chagas disease
@ast
Adverse events after the use of benznidazole in infants and children with Chagas disease
@en
Adverse events after the use of benznidazole in infants and children with Chagas disease
@nl
P2093
P356
P1433
P1476
Adverse events after the use of benznidazole in infants and children with Chagas disease
@en
P2093
Facundo Garcia-Bournissen
Guillermo Moscatelli
Hector Freilij
Samanta Moroni
P304
P356
10.1542/PEDS.2010-1172
P407
P577
2011-01-01T00:00:00Z